Argus Downgrades Abbvie (ABBV) to Hold as Humira faces U.S. competition
Tweet Send to a Friend
(Updated - April 5, 2023 9:12 AM EDT)
Argus analyst David Toung downgraded Abbvie (NYSE: ABBV) from Buy to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Argus analyst David Toung downgraded Abbvie (NYSE: ABBV) from Buy to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
